There is no effective therapy to treat Mycobacterium avium complex infection in patients with acquired immune deficiency syndrome. Clarithromycin (A-56268; TE-031) is a new macrolide which is twofold more active than erythromycin against most aerobic bacteria. In addition, higher levels in serum and tissue are achieved with clarithromycin than with erythromycin. In this study, clarithromycin, erythromycin, difloxacin, temafloxacin, ciprofioxacin, rifampin, amikacin, and ethambutol were tested in vitro and in vivo against the M. avium complex. The MICs for 90% of strains tested were 4 ,ug/mI for clarithromycin, 64 ,tg/ml for erythromycin, 32 tig/ml for difloxacin, 8 ,ug/ml for temafloxacin, 4 ,ug/ml for ciprofloxacin, 4 ,ug/ml for rifampin, 32 ,tg/ml for amikacin, and 32 ug/ml for ethambutol. Beige mice were infected intravenously with 1 CFU of M. avium ATCC 25291. Treatment was started on day 6 after infection and was administered twice a day at 8-h intervals for 9 days. Clarithromycin was the most effective compound in these tests and was effective in reducing the viable bacterial counts in the spleen when it was administered subcutaneously or orally at a dose of 25 mg/kg. Amikacin was the only other compound which showed activity in vivo. The peak concentration in serum at which clarithromycin was active was approximately 1.0 ,ug/mil.
1 CFU of M. avium ATCC 25291. Treatment was started on day 6 after infection and was administered twice a day at 8-h intervals for 9 days. Clarithromycin was the most effective compound in these tests and was effective in reducing the viable bacterial counts in the spleen when it was administered subcutaneously or orally at a dose of 25 mg/kg. Amikacin was the only other compound which showed activity in vivo. The peak concentration in serum at which clarithromycin was active was approximately 1.0 ,ug/mil.
The treatment of Mycobacterium avium complex infections in immunocompromised patients is a problem since no agent is clearly effective against these bacteria (8, 9) . We tested the activity of a new macrolide, clarithromycin (A-56268; TE-031) (2) , against the M. avium complex in vitro and also in the beige mouse model (1, 4) to determine whether it could be useful in treating these infections.
MATERIALS AND METHODS
Bacterial strains. Ten strains of the M. avium complex were clinical isolates obtained from Christopher Papasian (Veterans Administration Medical Center, Kansas City, Mo.), and two strains, M. avium ATCC 25291 and Mycobacterium intracellulare ATCC 13950, were from the American Type Culture Collection (Rockville, Md.).
Antibacterial agents. Clarithromycin (A-62671; 14-hydroxy metabolite of clarithromycin), erythromycin, ciprofloxacin, difloxacin, and temafloxacin were prepared at Abbott Laboratories (Abbott Park, Ill. 35°C . The plates were reincubated after they were read for up to 14 days, and the results were recorded again. The MIC was the lowest concentration of the antibacterial agent which allowed no growth.
Resistance frequency. The frequency of resistance to clarithromycin was determined by inoculating M. avium ATCC 25291 into Middlebrook 7H9 broth supplemented with 0.2% glycerol-0.2% glucose-10% OADC and incubating the culture for 24 days at 35°C. Serial 10-fold dilutions of this culture containing 6 x 109 CFU/ml were then prepared and b Significantly different from untreated controls (P < 0.05). The viable bacterial count at the time of medication was 6.62 ± 0.14 CFU/ml.
c Rifampin was administered orally. Other compounds were administered subcutaneously.
inoculated onto Middlebrook 7H10 agar supplemented with 0.5% glycerol; 10% OADC; and two, four, or eight times the MIC of clarithromycin or erythromycin. The MICs of erythromycin and clarithromycin were 16 and 2 ,ug/ml, respectively, for M. avium ATCC 25291. One set of plates had no antibiotic and was the growth control. The plates were incubated at 35°C for 14 days, and the colonies were counted. The plates were reincubated for a total of 21 days, and the colonies were counted again to ensure that all resistant colonies were counted. All plates were examined with a magnifying glass in order to detect tiny colonies. All viable counts were performed on duplicate plates.
In vivo tests in the beige mouse model. The beige mouse model has been described by Gangadharam et al. (4) . Beige mice (C57BL/6J bgJlbgJ) were obtained from Jackson Laboratory (Bar Harbor, Maine) and were infected by intravenous injection via the tail vein with 107 CFU of M. avium ATCC 25291 in 0.2 ml of physiological saline (0.85% [wt/vol] sodium chloride; Abbott Laboratories). This strain was found to cause a persistent infection in the beige mice. Treatment was started on day 6 after infection. Groups of 10 mice each were treated with two dose levels of each compound. All compounds except rifampin and clarithromycin were administered subcutaneously. Rifampin was administered orally, and clarithromycin was administered orally and subcutaneously. Rifampin was administered orally because it is well absorbed by this route and has been administered by this route previously (6) . Except for amikacin, rifampin, and ethambutol, the doses were selected to obtain concentrations in the blood which were similar to the achievable levels in blood in humans. Doses of amikacin (L. Kesavalu Pharmacokinetic studies. The levels of the compounds in blood were determined in C57BL/6J mice (Jackson Laboratory). Although these mice do not have a deficient immune system like the beige mice, they are similar to the beige mice in other respects. They were used instead of beige mice for the pharmacokinetic studies because of the limited availability of beige mice. The dose of each antibacterial agent and the route of administration for the pharmacokinetic studies were the same as those in the treatment experiments, except that a single dose was administered. Blood and spleens were collected from groups of five mice each at 0.5, 1, 2, 3, 6, and 24 h. The concentrations of the antibacterial agents in sera and spleens were determined by bioassay. The bioassay for clarithromycin has been described previously (3) . Blood active than erythromycin. Ciprofloxacin was the most active fluoroquinolone.
Resistance frequency. No M. avium colonies were selected on plates containing two, four, or eight times the MIC of clarithromycin; and the resistance frequency of M. avium ATCC 25291 was calculated to be <1.8 x 10-10 when tested with the three concentrations of clarithromycin. One resistant colony was selected at both four and eight times the MIC of erythromycin, and no colonies were selected at two times the MIC of erythromycin. The resistant colony was susceptible to >128 ,ug/ml, whereas the parent organism was susceptible to 16 ,ug/ml. The plates were incubated for as long as 21 days in order to determine whether any resistant colonies would grow after prolonged incubation. No other resistant colonies were found.
The resistance frequency for erythromycin was calculated to be 1.8 x 10-10 at four and eight times the MIC and <1.8
x 10-1°at two times the MIC. In vivo activity. In the first experiment, clarithromycin, temafloxacin, ciprofloxacin, difloxacin, and rifampin were tested at 10 and 25 mg/kg. All compounds except rifampin were administered subcutaneously. Rifampin was administered orally by gavage. The viable bacterial counts recovered from the spleens are given in Table 2 . At 10 and 25 mg/kg, clarithromycin was found to have a significantly different effect from those of all other treatment groups and decreased the viable bacterial counts by approximately 2 logl0 CFU. The fluoroquinolones and rifampin were not effective when tested as single agents.
In the second experiment, clarithromycin was administered orally by gavage at 50 and 100 mg/kg and subcutaneously at 10 and 25 mg/kg. Erythromycin and amikacin were tested subcutaneously at 10 and 25 mg/kg. Two combination treatments, clarithromycin-amikacin and amikacin-ethambutol-rifampin, were tested. The results are given in Table 3 . Clarithromycin was effective in reducing the bacterial counts after subcutaneous and oral therapies. The oral route of administration was as effective as the subcutaneous route for clarithromycin. When administered orally, amikacin was less effective than clarithromycin in reducing bacterial counts in the spleens. The number of bacteria recovered from the spleens of mice treated with combinations of amikacin and other drugs was similar to the number of bacteria recovered from mice treated with amikacin alone. The lowest dose at which clarithromycin was consistently effective in reducing viable bacterial counts by 1 log1o CFU/ml was 25 mg/kg when administered subcutaneously or orally (Table 4) .
Pharmacokinetics in mice. The concentrations of clarithromycin and test compounds in sera and spleens are given in Table 5 . Clarithromycin had a longer half-life in the sera and spleens than erythromycin did. Clarithromycin concentrations in the spleens were approximately 10 times those of the concentrations in sera. There was only a slight increase in the concentrations of clarithromycin in sera and spleens after 5 days of continuous therapy ( Table 6 ). The somewhat lower concentrations of clarithromycin in sera and spleens could be the result of enhanced metabolism after repeated administration.
DISCUSSION
Clarithromycin is a new macrolide which is well absorbed orally and has a longer half-life in serum than erythromycin does. It is twofold more active than erythromycin against most bacteria in the macrolide spectrum (2) . Therefore, it was surprising to find in this study that it was 8-to 32-fold more active than erythromycin in vitro against the M. avium (7) .
Among the compounds that were tested in this study, clarithromycin was the most active compound in vivo in three experiments. The in vivo activity of clarithromycin against M. avium may be related to the pharmacokinetic properties of the compound coupled with its in vitro activity and lower resistance frequency. Clarithromycin has been reported to achieve high concentrations in tissue (2) 417, 1986 ). Since clarithromycin is more acid stable than erythromycin, it is possible that it would remain active for a longer period of time than erythromycin in the acidic environment of the phagolysosome.
Combination therapy is generally used against mycobacteria to prevent resistance development. In our studies, the resistance frequency was <1.8 x 10-10 for M. avium ATCC 25291 when tested with clarithromycin. 
